Dicot Pharma

Dicot Pharma has been invited to present the company and its drug candidate LIB-01 at the annual Healthcare Life Sciences Conference organized by the U.S. investment bank Oppenheimer & Co. Inc. The conference highlights a broad range of public and private life science companies and attracts strong institutional interest. Attendance is by invitation only.

Longevity – living a long life in good health – is viewed as a growing trend within the biotechnology industry. In a research report, Oppenheimer highlights that new treatments for erectile dysfunction may play a significant role, and Dicot Pharma’s drug candidate LIB‑01 is identified as particularly promising for the future.

Dicot Pharma’s CEO Elin Trampe will present the company and the drug candidate LIB-01 for the treatment of erectile dysfunction. In October 2025, Dicot Pharma announced positive results from a clinical phase 2a study showing that LIB-01 produced an effect on erectile function that persisted for eight weeks after dosing. The company is also running a preclinical program in metabolic diseases.